The Academy is working across the research community and Government to understand and respond to the impacts of leaving the EU on UK medical sciences.Ongoing
Research and the European Union
On the 23 June 2016, the UK voted to leave the European Union. This represents one of the most profound challenges to the medical research sector in living memory, and the Academy is now working with the UK Government, devolved administrations and the wider research community to identify and undertake the bold actions needed to preserve the UK’s world-leading research environment.
The Academy is engaged with many ongoing activities:
- The President responded to the vote to reject the Prime Minister's Withdrawal Agreement on 12 March 2019.
- The Academy submitted written evidence to the Science and Technology Select Committee's Brexit, Science and Innovation: Preparations for a "no-deal" inquiry.
- The President responded to the vote on the Prime Minister's Brexit deal on 14 January 2019.
- The President wrote to all Fellows in January 2019 to outline the Academy's activities to ensure science and research is prioritised and protected as the UK leaves the EU.
- The Presidents of the UK National Academies wrote to the Home Sectretary on 16 November 2018 outlining the importance of internationalmobility for research and innovation.
- The Academy President welcomed a statement from the Federation of European Academies of Medicine on the importance of the UK to European research and the need to safeguard this relationship post Brexit.
- In October 2018, the Academy published a statement on the implications of leaving the EU without a deal. The President stressed these risks in an interview with BBC Radio 4's PM on Monday 1 October.
- The President responded to the Migration Advisory Committee report on EEA migrantion.
- The Academy signed a Future Partnership Project statement in May 2018.
- In March 2018, the President wrote to all Fellows outlining the Academy's priorities for Brexit and how we are working to ensure that these are prioritised during the negotitaions. This letter is also available as a blog on out website.
- The Academy of Medical Sciences hosted a discussion meeting with Pascal Lamy, Chair of the High Level Group on maximising the impact of EU Research & Innovation Programmes.
- In February 2018, the Academy's Treasurer Professor Anne Dell gave evidence to the House of Commons Science and Technology Committee Brexit Summit. Professor Dell highlighted the impacts of leaving the EU on the regulation of biomedical research. The Academy's written response to this inquiry is available on our website.
- The President welcomed progress on citizens’ rights and the confirmation that the UK will continue to participate in Horizon 2020 until its conclusion.
- The Academy President, Professor Sir Robert Lechler sits on the Minister's high level stakeholder working group on EU exit universities, research and innovation.
- The President responded to the Government's Future Partnership paper on Collaboration on science and innovation.
- Submitting evidence to the Health Committee on Brexit – medicines, medical devices and substances of human origin inquiry and the BEIS Committee on Brexit and implications for UK business: Pharmaceuticals.
- Submitting evidence to the Commons Exiting the EU Select Committee inquiry into 'UK's negotiating objectives for withdrawal from EU inquiry' in January 2017.
- Jointly submitting evidence to the Commons Home Affairs Committee inquiry into 'Immigration' in January 2017.
Prior to the referendum, the Academy sought to inform debate around the benefits and challenges of EU membership for UK research, by:
- Providing written and oral evidence to the House of Lords Science & Technology Committee inquiry into the impact of EU membership on research.
- Submitting written evidence to the House of Commons Science & Technology Committee inquiry which focused on the impact of EU regulations on UK life sciences.
- Issuing a statement highlighting the mobility, collaborative, funding and regulatory implications for research associated with a possible departure from the EU.
This report, jointly commissioned from the Technopolis Group by the UK’s four national academies – the Academy of Medical Sciences, the British Academy, the Royal Academy of Engineering and the Royal Society – explores exactly where EU funding goes, what kind of activities it supports and what other investment it attracts.
This work also commissioned a separate set of stand alone case studies which supplement the report and provide additional detail on particular funding streams, activities and regional support.
This report, commissioned by the eight leading UK medical organisations, highlights how the UK’s contribution to research throughout the EU has fostered and strengthened scientific co-operation. The executive summary can be found online here.
A series of eight case studies detailing specific aspects of the UK’s contribution to EU science and health is also available.
This report commissioned by the Academy of Medical Sciences, British Academy, Royal Academy of Engineering and Royal Society, presents the findings of a survey of 1,286 of the UK’s leading researchers (consisting of 762 Fellows and 524 grant recipients across the four national academies) to find out about the importance of international collaboration and mobility.